Key facts
- Portal Biotech’s last known valuation is $60.6M (Jun 2025).
- It has raised $58.0M; the latest was Early Stage VC ($47.4M) in Jun 2025.
- Notable investors include 8VC, British Business Bank, Earlybird Venture Capital, Pillar VC, Wilson Sonsini Goodrich & Rosati — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Portal Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Portal Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Portal Biotech
Operator of a biotechnology company intended to develop biosensing technology. The company utilizes bioengineered nanopores to analyze single-cell proteins and metabolites with unparalleled precision, enabling life science markets to get alternatives for their critical unmet needs.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2021
- Employees
- 34
- Website
- portalbiotech.com/
- Ownership
- Privately Held (backing)
Portal Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Portal Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Portal Biotech in its N-PORT filings yet. We sweep new filings monthly.